Antares Pharma, Inc. (ATRS)

EBITDA Growth

160.73%

TTM · Period ending:

ATRS logo

ATRS EBITDA Growth

Year-over-year change vs the same period a year earlier

Latest reported160.73%
ATRS TTM EBITDA YoY % (-34.98% → 160.73%)
High-resolution chart · PNG

ATRS ebitda growth history

Trailing twelve months (TTM). Each value covers four complete reported quarters.

Antares Pharma, Inc. EBITDA Growth — Trailing twelve months (TTM)
Period endingEBITDA Growth
160.7279%
322.5222%
88.681%
124.6863%
208.4326%
300.4658%
190.4236%
490.5412%
2,210.0559%
465.5018%
147.6988%
113.6726%
97.461%
91.6618%
23.0469%
7.1519%
27.2366%
40.1907%
39.6643%
33.2792%
1.8719%
-18.3151%
-8.6833%
-0.7298%
37.7872%
44.2106%
23.7098%
17.063%
-26.0368%
-69.9501%
-51.3167%
-73.126%
-73.6611%
-78.1685%
-207.9988%
-301.6744%
-398.7325%
-165.334%
-18.4011%
26.6932%
48.7585%
28.4544%
23.4902%
28.7915%
33.3154%
37.4611%
27.9342%
23.4452%
26.1687%
23.988%
9.3107%
-5.6507%
-33.3805%
-122.7137%
-81.1319%
-87.0605%
-51.2305%
26.7456%
27.0501%
35.4434%
28.5997%
4.7571%
3.4081%
6.3185%
0.8349%
-6.5466%
-7.9195%
69.5278%
73.6145%
76.2401%
75.2143%
-140.8844%
-201.5079%
-231.6394%
-198.9131%
-35.2418%
-20.4723%
-20.3742%
-59.4316%
-51.8249%
-59.9996%
-71.6764%
-111.3253%
-76.1976%
-47.202%
-41.9507%
28.7179%
28.1382%
23.4879%
37.3234%
-19.9422%
-40.8859%
-64.2033%
-95.5147%
-32.0886%
-37.5273%
-31.7429%
-34.9819%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.